NeuroPace (NASDAQ:NPCE) Trading Up 4% – Still a Buy?

Shares of NeuroPace, Inc. (NASDAQ:NPCE) shot up 4% during mid-day trading on Monday . The company traded as high as $11.65 and last traded at $11.47. 79,703 shares changed hands during trading, a decline of 17% from the average session volume of 95,657 shares. The stock had previously closed at $11.03.

Wall Street Analysts Forecast Growth

Separately, Wells Fargo & Company decreased their target price on NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.60.

NeuroPace Price Performance

The firm has a market cap of $342.36 million, a PE ratio of -11.47 and a beta of 2.05. The firm’s fifty day simple moving average is $8.42 and its two-hundred day simple moving average is $7.59. The company has a quick ratio of 4.77, a current ratio of 5.59 and a debt-to-equity ratio of 6.03.

NeuroPace (NASDAQ:NPCE) last issued its earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.07. The company had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same quarter in the prior year, the firm posted ($0.28) EPS. As a group, research analysts expect that NeuroPace, Inc. will post -1 EPS for the current year.

Insider Activity at NeuroPace

In other NeuroPace news, major shareholder Ltd. Kck sold 4,910 shares of NeuroPace stock in a transaction on Monday, October 7th. The shares were sold at an average price of $6.66, for a total value of $32,700.60. Following the sale, the insider now directly owns 5,540,104 shares in the company, valued at approximately $36,897,092.64. The trade was a 0.09 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last 90 days, insiders have sold 257,590 shares of company stock valued at $1,437,916. 22.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NPCE. Rhumbline Advisers purchased a new stake in shares of NeuroPace in the second quarter worth about $111,000. Financial Advocates Investment Management increased its stake in NeuroPace by 50.0% in the 2nd quarter. Financial Advocates Investment Management now owns 15,000 shares of the company’s stock worth $113,000 after acquiring an additional 5,000 shares during the last quarter. Barclays PLC raised its holdings in shares of NeuroPace by 346.0% during the 3rd quarter. Barclays PLC now owns 20,633 shares of the company’s stock worth $144,000 after acquiring an additional 16,007 shares in the last quarter. XTX Topco Ltd raised its holdings in shares of NeuroPace by 56.1% during the 2nd quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after acquiring an additional 8,643 shares in the last quarter. Finally, Bank of New York Mellon Corp bought a new position in shares of NeuroPace during the 2nd quarter valued at approximately $257,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.